Liu Yun, Xu Lai, Fang Yakun, Yan Chao
Department of Nephrology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, 266035, People's Republic of China.
Department of Obstetrics, Qingdao Municipal Hospital, Qingdao, 266071, People's Republic of China.
Cancer Manag Res. 2025 Sep 6;17:1911-1923. doi: 10.2147/CMAR.S524335. eCollection 2025.
In view of the differences in the clinical efficacy of I radioactive particle brachytherapy for head and neck tumors, this study aims to systematically analyze the key factors affecting its efficacy, and build a reliable prediction model to provide a scientific basis for clinical precise evaluation and personalized treatment plan formulation.
Retrospective analysis of 174 patients (2020-2024) divided into training (n=122) and validation (n=52) sets. Efficacy was assessed using RECIST criteria. Lasso Logistic regression identified independent factors, and a nomogram model was constructed and evaluated.
The study confirmed that patients' age, tumor stage, tumor diameter, particle implantation dose and serum tumor marker level were independent factors affecting the clinical efficacy (<0.05). The nomogram prediction model has excellent performance, and the c-index values in the training set and the validation set are 0.867 and 0.725, respectively, showing good discrimination ability; The results of calibration curve showed that the predicted value was in good agreement with the actual value, and the average absolute errors of the two groups were 0.114 and 0.133, respectively; In Hosmer lemeshow test, the training set =7.422 (=0.491), the validation set =12.086 (=0.147), suggesting that the model fitting effect is ideal; The area under the ROC curve in the training set and the validation set was 0.860 (95% CI:0.767-0.953) and 0.750 (95% CI:0.501-0.999), respectively, which showed high sensitivity and specificity.
The model effectively predicts I brachytherapy outcomes, aiding clinical evaluation and supporting precision treatment for head and neck tumors.
鉴于碘放射性粒子近距离治疗头颈部肿瘤的临床疗效存在差异,本研究旨在系统分析影响其疗效的关键因素,并建立可靠的预测模型,为临床精准评估和个性化治疗方案制定提供科学依据。
回顾性分析2020年至2024年的174例患者,分为训练集(n = 122)和验证集(n = 52)。采用RECIST标准评估疗效。Lasso逻辑回归确定独立因素,并构建和评估列线图模型。
研究证实患者年龄、肿瘤分期、肿瘤直径、粒子植入剂量和血清肿瘤标志物水平是影响临床疗效的独立因素(<0.05)。列线图预测模型具有优异的性能,训练集和验证集的c指数值分别为0.867和0.725,显示出良好的区分能力;校准曲线结果表明预测值与实际值吻合良好,两组的平均绝对误差分别为0.114和0.133;在Hosmer lemeshow检验中,训练集χ² = 7.422(P = 0.491),验证集χ² = 12.086(P = 0.147),表明模型拟合效果理想;训练集和验证集的ROC曲线下面积分别为0.860(95%CI:0.767 - 0.953)和0.750(95%CI:0.501 - 0.999),显示出高敏感性和特异性。
该模型有效预测碘近距离治疗结果,有助于临床评估并支持头颈部肿瘤的精准治疗。